Gene:
BCR
breakpoint cluster region

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.



last updated 12/13/2013

FDA Label for bosutinib monohydrate and ABL1, BCR

This label is on the FDA Biomarker List
Genetic testing required

Summary

The FDA-approved drug label for bosutinib (BOSULIF) notes that it is intended for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for busulfan and ABL1, BCR

This label is on the FDA Biomarker List
Actionable PGx

Summary

The busulfan FDA-approved drug label states it is less effective in patients with chronic myelogenous leukemia who lack the Philadelphia (Ph1) chromosome. Testing for the BCR-ABL1 gene fusion is not mentioned in the drug label.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for dasatinib and ABL1, BCR

This label is on the FDA Biomarker List
Genetic testing required

Summary

The FDA-approved drug label for dasatinib (SPRYCEL) notes that it is intended for adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) or acute lymphoblastic leukemia (Ph+ ALL) and resistance or intolerance to prior therapy.

There's more of this label. Read more.


last updated 12/18/2013

FDA Label for homoharringtonine and ABL1, BCR

This label is on the FDA Biomarker List
Informative PGx

Summary

The FDA-approved drug label for omacetaxine mepesuccinate (homoharringtonine; SYNRIBO) notes that it is intended for adults with chronic or accelerated phase chronic myeloid leukemia (CML). The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for imatinib and ABL1, BCR, KIT

This label is on the FDA Biomarker List
Genetic testing required

Summary

The decision of whether to treat patients with imatinib is based on the presence of genetic biomarkers, including BCR-ABL (the Philadelphia chromosome), KIT, and PDGFR gene rearrangements.

There's more of this label. Read more.


last updated 10/25/2013

FDA Label for nilotinib and ABL1, BCR, UGT1A1

This label is on the FDA Biomarker List
Genetic testing required

Summary

Nilotinib is indicated for use in patients diagnosed with Philadelphia chromosome positive (presence of a BCR-ABL1 gene fusion) chronic myeloid leukemia, due to its mechanism of action. Individuals with the UGT1A1*28 genotype (TA)7/(TA)7 (rs8175347) are at an increased risk of hyperbilirubinemia when taking nilotinib (testing is not required for UGT1A1).

There's more of this label. Read more.


last updated 12/19/2013

FDA Label for ponatinib and ABL1, BCR

This label is on the FDA Biomarker List
Actionable PGx

Summary

The FDA-approved drug label for ponatinib (Iclusig) states that it is intended for adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or intolerant to prior tyrosine kinase inhibitor therapy, including those with the BCR-ABL T315I mutation. The majority of patients with CML are positive for the Philadelphia chromosome (BCR-ABL1 gene fusion).

There's more of this label. Read more.


last updated 03/31/2014

European Medicines Agency (EMA) Label for bosutinib monohydrate and ABL1, BCR

Genetic testing required

Summary

The EMA EPAR for bosutinib (Bosulif) contains information regarding the indication of the drug in adult patients with Philadelphia chromosome positive chronic myelogenous leukaemia. This is due to its mechanism of action - the drug inhibits the abnormal BCR-ABL kinase that promotes chronic myelogenous leukaemia.

There's more of this label. Read more.


last updated 10/25/2013

European Medicines Agency (EMA) Label for dasatinib and ABL1, BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the indication of Dasatinib (Sprycel) in patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia or acute lymphoblastic leukaemia.

There's more of this label. Read more.



last updated 10/27/2013

European Medicines Agency (EMA) Label for nilotinib and ABL1, BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for nilotinib (Tasigna) states it is indicated for patients who have Philadelphia chromosome-positive (presence of a BCR-ABL1 gene fusion) chronic myelogenous leukemia (CML). The label differs from that of the FDA as it does not contain any information regarding UGT1A1 genotype.

There's more of this label. Read more.


last updated 06/13/2014

European Medicines Agency (EMA) Label for ponatinib and ABL1, BCR

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) for ponatinib (Iclusig) states that indications of the drug include patients with Philadelphia chromosome positive (BCR-ABL1 gene fusion) acute lymphoblastic leukemia who are resistant or intolerant to dasatinib or patients who have the BCR-ABL T315I mutation, due to its mechanism of action as an inhibitor of BCR-ABL and inhibitor of mutant forms of the ABL kinase.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?
BCR-ABL Quantitation; ABL Kinase Domain Sequencing BCR-ABL (reciprocal translocation involving chromosomes 9 and 22, t(9,22)(q34, q11))

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs140504 109818A>G, 23627369A>G, 2387A>G, 3017938A>G, Asn796Ser
A > G
Missense
Asn796Ser
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138

Overview

Alternate Names:  None
Alternate Symbols:  ALL; CML; D22S662; PHL
PharmGKB Accession Id: PA25321

Details

Cytogenetic Location: chr22 : q11.23 - q11.23
GP mRNA Boundary: chr22 : 23522552 - 23660224
GP Gene Boundary: chr22 : 23512552 - 23663224
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Bipolar Disorder

Publications related to BCR: 6

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rho Kinase Regulates the Survival and Transformation of Cells Bearing Oncogenic Forms of KIT, FLT3, and BCR-ABL. Cancer cell. 2011. Mali Raghuveer Singh, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011. Boulos Nidal, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010. McCarthy Michael J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cancer biomarker problem. Nature. 2008. Sawyers Charles L. PubMed

LinkOuts

Entrez Gene:
613
OMIM:
151410
608232
613065
UCSC Genome Browser:
NM_004327
RefSeq RNA:
NM_004327
NM_021574
RefSeq Protein:
NP_004318
NP_067585
RefSeq DNA:
AC_000065
AC_000154
NC_000022
NG_009244
NT_011520
NW_001838745
NW_927628
UniProtKB:
BCR_HUMAN (P11274)
Ensembl:
ENSG00000186716
GenAtlas:
BCR
GeneCard:
BCR
MutDB:
BCR
ALFRED:
LO015393V
HuGE:
BCR
Comparative Toxicogenomics Database:
613
ModBase:
P11274
HumanCyc Gene:
HS09933
HGNC:
1014

Common Searches